0000000000115649

AUTHOR

Bettina E. Hansen

showing 4 related works from this author

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis…

2019

Wong, Grace LH/0000-0002-2863-9389; Wong, Vincent WS/0000-0003-2215-9410; Mangia, A/0000-0002-2600-3555; Brahmania, Mayur/0000-0002-4671-1479; Chan, Henry Lik-Yuen/0000-0002-7790-1611; Brouwer, Willem Pieter/0000-0001-8713-1481; Feld, Jordan/0000-0003-2640-2211; Tanwandee, Tawesak/0000-0001-7634-0843; Jaroszewicz, Jerzy/0000-0003-0139-4753; Chuaypen, Natthaya/0000-0002-5415-510X

0301 basic medicineMicrobiology (medical)AdultMaleHBsAgHepatitis B virusSettore MED/09 - Medicina InternaGenotyping TechniquesGenome-wide association studymedicine.disease_causePeripheral blood mononuclear cellAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicSDG 3 - Good Health and Well-beingPegylated interferonInterferonmedicineHumansGWASchronic hepatitis BgeneticsProspective StudiespeginterferonArticles and CommentariesHepatitis B virusresponsebusiness.industryInterleukinInterferon-alphaMiddle Aged3. Good health030104 developmental biologyInfectious DiseasesHBeAgImmunologyMultivariate Analysis030211 gastroenterology & hepatologyFemaleInterferonsbusinessmedicine.drugGenome-Wide Association StudyClinical Infectious Diseases
researchProduct

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

2004

Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 b…

AdultMalemedicine.medical_specialtyPlus ribavirinCirrhosisHepatocellular-CarcinomaAdolescentFibrosiPopulationAlpha interferonAntiviral AgentsSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansDecompensationeducationSurvival analysisAgededucation.field_of_studyCirrhosibusiness.industryIncidence (epidemiology)Follow-upNatural-historyGastroenterologyCohortHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurvival AnalysisImpactTreatment OutcomeLiverHepatocellular carcinomaImmunologyRegression AnalysisFemaleTherapyInterferonsbusinessAlpha-interferonGut
researchProduct

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

2017

Background & Aims: The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR). We aimed to assess the risk of cirrhosis-related complications in this specific group of patients. Methods: Data from previously reported Western cohort studies including patients with chronic HCV infection and bridging fibrosis or cirrhosis who attained SVR were pooled for survival analyses on the individual patient level. The primary endpoint was HCC and the secondary endpoint was clinical disease progression, defined as liver failure, HCC or death. Results: Included were 1…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSustained Virologic ResponseHepatitis C virusmedicine.disease_causeGastroenterologyCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineSDG 3 - Good Health and Well-beingRisk FactorsDiabetes mellitusInternal medicinemedicineClinical endpointHumansAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemalebusinessLiver cancer
researchProduct

The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transpl…

2020

BACKGROUND There is a lack of data on the use of direct-acting antivirals (DAA) on the risk of death and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) listed for liver transplantation (LT). We aimed to assess the impact of antiviral treatment on mortality and HCC recurrence patients with HCC-HCV. METHODS This was a retrospective multicenter study of patients with HCC-HCV listed for LT from 2005 to 2015. Patients were divided according to the antiviral treatment received after HCC diagnosis: DAA, interferon (IFN), or no antiviral. Intention-to-treat overall survival and HCC recurrence incidence were compared by the Kaplan-Meier method. Multiva…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsWaiting Listsmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterologyAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsInternal medicineCarcinomamedicineHumansRisk factorRetrospective StudiesTransplantationbusiness.industryIncidence (epidemiology)Hazard ratioLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence LocalbusinessTransplantation
researchProduct